Erratum: Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses (Journal of Virology (2016) 90: 9 (4720–4734) DOI: 10.1128/jvi.03152-15);Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses

Journal of Virology

Volumn 90, Issue 9, 2016, Pages 4720-4734

  Carter, Donald M ^a   Darby, Christopher A ^a   Lefoley, Bradford C ^a   Crevar, Corey J ^b   Alefantis, Timothy ^c   Oomen, Raymond ^c   Anderson, Stephen F ^c   Strugnell, Tod ^c   Cortés Garcia, Guadalupe ^c   Vogel, Thorsten U ^c   Parrington, Mark ^c   Kleanthous, Harold ^c   Ross, Ted M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Vaccine and Gene Therapy Institute   (United States)

^c SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; PROTEIN BINDING; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS LIKE PARTICLE VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SEASONAL INFLUENZA; SEQUENCE ALIGNMENT; TREATMENT RESPONSE; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; CELL LINE; CHEMISTRY; CLASSIFICATION; DISEASE MODEL; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFLUENZA, HUMAN; METABOLISM; MOLECULAR MODEL; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN CONFORMATION; PROTEIN DOMAIN; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; DISEASE MODELS, ANIMAL; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MODELS, MOLECULAR; ORTHOMYXOVIRIDAE INFECTIONS; PHYLOGENY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84964924240     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/jvi.01813-23     Document Type: Erratum

References (46)

1. Ellebedy AH, Webby RJ. 2009. Influenza vaccines. Vaccine 27(Suppl 4):D65-D68. http://dx.doi.org/10.1016/j.vaccine.2009.08.038.
2. Monto AS. 2010. Seasonal influenza and vaccination coverage. Vaccine 28(Suppl 4):D33-D44. http://dx.doi.org/10.1016/j.vaccine.2010.08.027.
3. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha DQ, Farrar J, de Jong MD, Lanzavecchia A, Subbarao K. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4:e178. http://dx.doi.org/10.1371/journal.pmed.0040178.
4. Puck JM, Glezen WP, Frank AL, Six HR. 1980. Protection of infants from infection with influenzaAvirus by transplacentally acquired antibody. J Infect Dis 142:844-849. http://dx.doi.org/10.1093/infdis/142.6.844.
5. Murphy BR, Clements ML. 1989. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 146:107-116.
6. Frasca D, Diaz A, Romero M, Landin AM, Phillips M, Lechner SC, Ryan JG, Blomberg BB. 2010. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 28:8077-8084. http://dx.doi.org/10.1016/j.vaccine.2010.10.023.
7. Goronzy JJ, Weyand CM. 2013. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 14:428-436. http://dx.doi.org/10.1038/ni.2588.
8. Rao S, Kong W-P, Wei C-J, Van Hoeven N, Gorres J, Nason M, Andersen H, Tumpey T, Nabel G. 2010. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 5:e9812. http://dx.doi.org/10.1371/journal.pone.0009812.
9. Kirchenbaum GA, Ross TM. 2014. Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol 28:71-76. http://dx.doi.org/10.1016/j.coi.2014.02.005.
10. Crevar CJ, Carter DM, Lee KY, Ross TM. 2015. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades. Hum Vaccin Immunother 11:572-583. http://dx.doi.org/10.1080/21645515.2015.1012013.
11. Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM. 2012. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol 19: 128-139. http://dx.doi.org/10.1128/CVI.05533-11.
12. Giles BM, Crevar CJ, Carter DM, Bissel SJ, Schultz-Cherry S, Wiley CA, Ross TM. 2012. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 205:1562-1570. http://dx.doi.org/10.1093/infdis/jis232.
13. Giles BM, Ross TM. 2011. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive anti-bodies in mice and ferrets. Vaccine 29:3043-3054. http://dx.doi.org/10.1016/j.vaccine.2011.01.100.
14. Ross TM, Xu Y, Bright RA, Robinson HL. 2000. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1:127-131. http://dx.doi.org/10.1038/77802.
15. Soding J. 2005. Protein homology detection by HMM-HMM comparison. Bioinformatics 21:951-960. http://dx.doi.org/10.1093/bioinformatics/bti125.
16. Soding J, Biegert A, Lupas AN. 2005. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res 33:W244-W248. http://dx.doi.org/10.1093/nar/gki408.
17. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772-780. http://dx.doi.org/10.1093/molbev/mst010.
18. Askonas B, McMichael A, Webster RG. 1982. The immune response to influenza viruses and the problem of protection against infection, p 159-188 In Beare AS (ed), Basic and applied influenza research. CRC Press, Boca Raton, FL.
19. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
20. US Congress. 1966. Animal Welfare Act of 1966 intended to regulate the transport, sale and handling of dogs, cats, guinea pigs, nonhuman primates, hamsters and rabbits intended to use for research or other purposes. Public Law 89-544. United States Code, Title 7. Sections 2131-2156.
21. US Department of Health and Human Services. 2009. Biosafety in microbiological and biomedical laboratories, 5th ed. HHS publication no. (CDC) 21-1112. US Department of Health and Human Services, Washington, DC.
22. Gillim-Ross L, Subbarao K. 2006. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 19:614-636. http://dx.doi.org/10.1128/CMR.00005-06.
23. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-1181. http://dx.doi.org/10.1016/S0140-6736(05)67338-2.
24. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM. 2003. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 308:270-278. http://dx.doi.org/10.1016/S0042-6822(03)00008-4.
25. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894. http://dx.doi.org/10.1001/jama.295.8.joc60020.
26. Mitchell JA, Green TD, Bright RA, Ross TM. 2003. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21:902-914. http://dx.doi.org/10.1016/S0264-410X(02)00539-X.
27. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108:14216-14221. http://dx.doi.org/10.1073/pnas.1111497108.
28. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe JE, Jr. 2011. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol 187:3704-3711. http://dx.doi.org/10.4049/jimmunol.1101823.
29. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE, Jr. 2011. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85:10905-10908. http://dx.doi.org/10.1128/JVI.00700-11.
30. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67:2552-2558.
31. Carter DM, Bloom CE, Nascimento EJ, Marques ET, Craigo JK, Cherry JL, Lipman DJ, Ross TM. 2013. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J Virol 87:1400-1410. http://dx.doi.org/10.1128/JVI.02257-12.
32. Carter DM, Lu HR, Bloom CE, Crevar CJ, Cherry JL, Lipman DJ, Ross TM. 2012. Complex patterns of human antisera reactivity to novel 2009 H1N1 and historical H1N1 influenza strains. PLoS One 7:e39435. http://dx.doi.org/10.1371/journal.pone.0039435.
33. Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy AH, Carter DM, Andrews SF, Zheng NY, Huang M, Huang Y, Strauss D, Shaz BH, Hodinka RL, Reyes-Teran G, Ross TM, Wilson PC, Ahmed R, Bloom JD, Hensley SE. 2014. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci U S A 111:15798-15803. http://dx.doi.org/10.1073/pnas.1409171111.
34. Ross TM, Lin CJ, Nowalk MP, Huang HH, Spencer SM, Shay DK, Sambhara S, Sundaram ME, Friedrich T, Sauereisen S, Bloom CE, Zimmerman RK. 2014. Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age. Hum Vaccin Immunother 10:1195-1203. http://dx.doi.org/10.4161/hv.28313.
35. Zhang H, Wang L, Compans RW, Wang BZ. 2014. Universal influenza vaccines, a dream to be realized soon. Viruses 6:1974-1991. http://dx.doi.org/10.3390/v6051974.
36. Jang YH, Seong BL. 2014. Options and obstacles for designing a universal influenza vaccine. Viruses 6:3159-3180. http://dx.doi.org/10.3390/v6083159.
37. Kirchenbaum GA, Carter DM, Ross TM. 2015. Sequential infection in ferrets with antigenically distinct seasonal H1N1 influenza viruses boosts hemagglutinin stalk-specific antibodies. J Virol 90:1116-1128. http://dx.doi.org/10.1128/JVI.02372-15.
38. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007.
39. DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20:143-151. http://dx.doi.org/10.1038/nm.3443.
40. Ellebedy AH, Ahmed R. 2012. Re-engaging cross-reactive memory B cells: the influenza puzzle. Front Immunol 3:53. http://dx.doi.org/10.3389/fimmu.2012.00053.
41. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly crossreactive memory B cells. Proc Natl Acad Sci U S A 109:9047-9052. http://dx.doi.org/10.1073/pnas.1118979109.
42. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, de Man M, Ding Z, Apetri A, Kukrer B, Sneekes-Vriese E, Tomkiewicz D, Laursen NS, Lee PS, Zakrzewska A, Dekking L, Tolboom J, Tettero L, van Meerten S, Yu W, Koudstaal W, Goudsmit J, Ward AB, Meijberg W, Wilson IA, Radosevic K. 2015. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349:1301-1306. http://dx.doi.org/10.1126/science.aac7263.
43. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang L, Zhang Y, Joyce MG, Lingwood D, Moin SM, Andersen H, Okuno Y, Rao SS, Harris AK, Kwong PD, Mascola JR, Nabel GJ, Graham BS. 2015. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21:1065-1070. http://dx.doi.org/10.1038/nm.3927.
44. Tsang TK, Cauchemez S, Perera RA, Freeman G, Fang VJ, Ip DK, Leung GM, Malik Peiris JS, Cowling BJ. 2014. Association between antibody titers and protection against influenza virus infection within households. J Infect Dis 210:684-692. http://dx.doi.org/10.1093/infdis/jiu186.
45. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF, Guindon S, Lefort V, Lescot M, Claverie JM, Gascuel O. 2008. Phylogeny.fr: robust phylogenetic analysis for the nonspecialist. Nucleic Acids Res 36:W465-W469. http://dx.doi.org/10.1093/nar/gkn180.
46. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, Tatusova T, Ostell J, Lipman D. 2008. The influenza virus resource at the National Center for Biotechnology Information. J Virol 82:596-601. http://dx.doi.org/10.1128/JVI.02005-07.